A phase 1, open label, multi-center, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma [CN1-101].

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date27/08/2031/12/22


  • Medical Oncology
  • Clinical trial